Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Cameron grandmother calls for Maytag oven recall after her stove explodes
Recommended
Map shows parts of western NC open for tourism
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
173.79
-0.21 (-0.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,456,187
Open
173.65
Bid (Size)
173.66 (1)
Ask (Size)
175.00 (3)
Prev. Close
174.00
Today's Range
173.14 - 175.99
52wk Range
173.14 - 268.30
Shares Outstanding
144,000,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
Biogen Analysts Slash Their Forecasts After Q3 Results
October 31, 2024
Via
Benzinga
Performance
YTD
-35.08%
-35.08%
1 Month
-5.95%
-5.95%
3 Month
-12.40%
-12.40%
6 Month
-21.51%
-21.51%
1 Year
-30.34%
-30.34%
More News
Read More
This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
October 31, 2024
Via
Benzinga
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum
October 30, 2024
Via
Investor's Business Daily
Looking Into Biogen's Recent Short Interest
October 22, 2024
Via
Benzinga
The Latest Analyst Ratings For Biogen
October 10, 2024
Via
Benzinga
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
October 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Via
Benzinga
Biogen (BIIB) Q3 2024 Earnings Call Transcript
October 30, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook
October 30, 2024
Via
Benzinga
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 29, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
October 29, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
October 29, 2024
From
Biogen Inc.
Via
GlobeNewswire
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
October 28, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
October 26, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
October 24, 2024
From
Biogen Inc.
Via
GlobeNewswire
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
October 23, 2024
Via
The Motley Fool
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
October 22, 2024
From
Biogen Inc.
Via
GlobeNewswire
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
October 17, 2024
Via
Benzinga
Topics
Workforce
Exposures
Layoff
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
October 16, 2024
Via
Benzinga
Exposures
Product Safety
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
October 14, 2024
Via
Benzinga
Large-Cap Stocks In Trouble - Sunday, Oct. 13
October 13, 2024
Via
Talk Markets
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
October 10, 2024
Via
MarketBeat
Topics
ETFs
Earnings
Exposures
Financial
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
October 09, 2024
From
Biogen Inc.
Via
GlobeNewswire
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
October 08, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.